The FDA has granted marketing authorization to CT-132, an adjunctive, prescription digital therapeutic for the preventive treatment of episodic migraine.
Read the full article at: www.medscape.com
The FDA has granted marketing authorization to CT-132, an adjunctive, prescription digital therapeutic for the preventive treatment of episodic migraine.
Read the full article at: www.medscape.com